Stanford



Brandon Bergsneider

Resident in Neurosurgery

Bio

BIO

Brandon Bergsneider was born and raised in Los Angeles, CA. Brandon earned a BS in Human Biology from Stanford and an MSc in Bioinformatics and Theoretical Systems Biology from Imperial College London as a Fulbright Scholar. Prior to medical school, he also received the NIH Cancer Research Training Award to pursue a yearlong research fellowship at the NIH Neuro-Oncology Branch. He received his MD from the Stanford University School of Medicine as a Knight-Hennessy Scholar, and conducted research under the mentorship of Dr. Michael Lim and Dr. Christina Jackson, using multi-omic technologies to characterize the brain tumor microenvironment, elucidate predictors of response to immunotherapy, and identify novel immunotherapeutic targets. Brandon's work has been published in several high-impact journals including Science, Immunity, Cancer Immunology Research, Oncoimmunology, Journal of Neuro-Oncology, Neuro-Oncology Advances, and Bioinformatics. Prior to pursuing medicine, Brandon used to work as a surf instructor, and in his free time he enjoys going surfing and sharing his love for the sport with others.

Publications

PUBLICATIONS

- **Cross-species transcriptomic integration reveals a MIRO1-mediated macrophage-T cell axis in glioma.** *Life science alliance*
  Du, Z., Li, M., Bergsneider, B. H., Tsai, A. P., Cho, K. B., Kim, L. H., Choi, J., Li, G., Wyss-Coray, T., Lim, M., Wang, X.
  2026; 9 (8)
- **Biomarkers for predicting immunotherapy response and resistance in glioblastoma.** *Frontiers in immunology*
  Kim, S., Abikenari, M., Bergsneider, B., Kim, L. H., Lim, M.
  2026; 17: 1823338
- **Precision Immunotherapeutics for Glioblastoma: Current Approaches and Emerging Strategies in 2026.** *Cells*
  Poe, J., Kim, C., Coleman, C., Nguyen, H., Velazhahan, V., Bergsneider, B., Sanker, V., Kim, S., Chen, Y., Abikenari, M., Choi, J., Lim, M.
  2026; 15 (6)
- **Nexus of IDO1/Kynurenine Pathway to T-Cell Exhaustion: Hypoxia-Induced Tryptophan Metabolism in Glioblastoma.** *Metabolites*
  Abikenari, M., Nageeb, G., Ha, J. H., Sjoholm, M. A., Liu, J., Bergsneider, B., Valenzuela, J., Poe, J., Bog Cho, K., Verma, R., Wu, C., Sanker, V., Medikonda, et al
  2026; 16 (3)
- **Adaptive immunotherapeutic paradigms in diffuse midline glioma: integrating epigenetic reprogramming, neuron-glioma interactions, and tumor microenvironment modulation.** *Journal of neuro-oncology*
  Liu, J., Ha, J. H., Abikenari, M., Sjoholm, M. A., Annagiri, S., Ravi, K., Bergsneider, B. H., Verma, R., Theodros, D., Medikonda, R., Li, G., Prolo, L. M., Monje, et al
  2025; 176 (2): 144
- **Spatially Encoded Oncogenesis and Transcriptional Plasticity in Meningioma: Drivers of Therapeutic Resistance and Opportunities for Targeted Intervention.** *Cancers*

Abikenari, M. A., Regev, A., Bergsneider, B. H., Himic, V., Annagiri, S., Kim, L. H., Medikonda, R., Choi, J., Jeyaretna, S., Fountain, D. M., Lim, M.
2025; 17 (16)

- **Distinct myeloid-derived suppressor cell populations in human glioblastoma.** *Science (New York, N.Y.)*
  Jackson, C., Cherry, C., Bom, S., Dykema, A. G., Wang, R., Thompson, E., Zhang, M., Li, R., Ji, Z., Hou, W., Zhan, W., Zhang, H., Choi, et al
  2025; 387 (6731): eabm5214

- **PRONA: An R-package for Patient Reported Outcomes Network Analysis.** *Bioinformatics (Oxford, England)*
  Bergsneider, B. H., Celiku, O.
  2024

- **Symptom Network Analysis and Unsupervised Clustering of Oncology Patients Identifies Drivers of Symptom Burden and Patient Subgroups With Distinct Symptom Patterns.** *Cancer medicine*
  Bergsneider, B. H., Armstrong, T. S., Conley, Y. P., Cooper, B., Hammer, M., Levine, J. D., Paul, S., Miaskowski, C., Celiku, O.
  2024; 13 (19): e70278

- **The CCR6-CCL20 axis promotes regulatory T cell glycolysis and immunosuppression in tumors.** *Cancer immunology research*
  Pant, A., Jain, A., Chen, Y., Patel, K., Saleh, L., Tzeng, S., Nitta, R. T., Zhao, L., Wu, C. Y., Bederson, M., Wang, W. L., Bergsneider, B. H., Choi, et al
  2024

- **The cytokine Meteorin-like inhibits anti-tumor CD8+ T cell responses by disrupting mitochondrial function.** *Immunity*
  Jackson, C. M., Pant, A., Dinalankara, W., Choi, J., Jain, A., Nitta, R., Yazigi, E., Saleh, L., Zhao, L., Nirschl, T. R., Kochel, C. M., Hwa-Lin Bergsneider, B., Routkevitch, et al
  2024

- **CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy.** *Oncoimmunology*
  Pant, A., Hwa-Lin Bergsneider, B., Srivastava, S., Kim, T., Jain, A., Bom, S., Shah, P., Kannapadi, N., Patel, K., Choi, J., Cho, K. B., Verma, R., Yu-Ju Wu, et al
  2024; 13 (1): 2338965

- **Discovery of clinical and demographic determinants of symptom burden in primary brain tumor patients using network analysis and unsupervised clustering.** *Neuro-oncology advances*
  Bergsneider, B. H., Vera, E., Gal, O., Christ, A., King, A. L., Acquaye, A., Choi, A., Leeper, H. E., Mendoza, T., Boris, L., Burton, E., Lollo, N., Panzer, et al
  2023; 5 (1): vdac188

- **Analysis of SARS-CoV-2 infection associated cell entry proteins ACE2, CD147, PPIA, and PPIB in datasets from non SARS-CoV-2 infected neuroblastoma patients, as potential prognostic and infection biomarkers in neuroblastoma.** *Biochemistry and biophysics reports*
  Bergsneider, B., Bailey, E., Ahmed, Y., Gogineni, N., Huntley, D., Montano, X.
  2021; 27: 101081

- **Next-Generation Sequencing and Personalized Medicine for Brain Cancer** *CURRENT SURGERY REPORTS*
  Bergsneider, B. H., Liau, L. M.
  2018; 6 (12)